Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Sees Significant Decline in Short Interest

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the recipient of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 13,529 shares, a drop of 60.5% from the February 26th total of 34,253 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily trading volume, of 17,426 shares, the short-interest ratio is currently 0.8 days.

Alaunos Therapeutics Stock Down 1.8%

NASDAQ:TCRT traded down $0.06 during trading hours on Thursday, reaching $3.09. 4,247 shares of the company’s stock were exchanged, compared to its average volume of 19,532. Alaunos Therapeutics has a 1-year low of $1.31 and a 1-year high of $6.20. The firm has a market capitalization of $7.16 million, a price-to-earnings ratio of -1.34 and a beta of -1.29. The company has a 50-day moving average of $2.97 and a 200 day moving average of $3.04.

Hedge Funds Weigh In On Alaunos Therapeutics

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. HRT Financial LP purchased a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned 0.54% of Alaunos Therapeutics as of its most recent SEC filing. 27.72% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Alaunos Therapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.